Search 

RiverVest Venture Partners is a venture capital firm that was founded in 2000 and is based in St. Louis, Missouri with additional office in Cleveland, Ohio. The firm currently has managed over $208 million of total assets. RiverVest has raised two investment funds with total committed capital of $165 million since inception. The recent fund closed at $75 million. RiverVest typically makes equity investments into global companies, and has no specific geographic preferences. The firm will consider making investments at all the stages, and focuses on investments in seed, early-stage and select later-stage companies. The typical investment size is around $6 million, though the firm can invest more or less, depending on the opportunity. 

RiverVest is extremely opportunistic when it comes to investments in the life sciences space; with that being said RiverVests specified sectors and sub sectors of interest may or may not be an area in which RiverVest is currently looking to allocate capital to. The firm invests in companies in the biotech therapeutics and diagnostics, as well the medical technology space. 

Some of the firms investments have included companies developing biotech therapeutics and diagnostics targeting diseases of the blood and blood forming organs, neoplasms, cancer, and oncology, skin and subcutaneous tissue, cardiovascular diseases, diseases of the ear, and infectious diseases. The firm has also invested in companies developing anti-body based therapeutics. The firm has also invested in firms developing medical technologies such as therapeutic radiation devices, active implantable devices, non active implantable devices, hospital hardware, and imaging devices.

F. Hoffmann-La Roche Ltd. is a Swiss global health-care company that operates worldwide under two divisions: Pharmaceuticals and Diagnostics. Roche is looking for first-in-class or best-in-class opportunities that address diseases of unmet medical need and have the potential to revolutionize the standard of care. Roche focuses on their main disease therapy areas – oncology and Immuno-oncology, ophthalmology, infectious diseases and neurosciences–as well as looking at opportunities in promising technologies and early-stage collaborations. Beyond the asset, Roche always look for the right partnership and cultural fit. Roche also seeks collaboration in diagnostics, specifically biomarkers.

Regulating Nitrosylation for Multi-Disease Therapies

SAJE Pharma’s S‑nitrosoglutathione reductase (GSNOR) inhibition technology regulates nitric oxide signal transduction pathways that are critical for multiple therapeutic benefits.  SAJE’s small molecule drugs regulate nitrosylation by inhibiting GSNOR.  Many biologists consider that “Nitrosylation is the new phosphorylation”, meaning that nitrosylation regulates cell pathways as directly as does phosphorylation.  The big advantage for SAJE is that there is only one human GSNOR to inhibit as compared to 100’s of phosphorylation targets, making it a much more “druggable” target with less possibility for off-target toxicity.  SAJE and its collaborators have discovered that GSNOR inhibition reduces: inflammation, oxidant damage, fibrosis, mucus accumulation, and bronchoconstriction.  Such multiple therapeutic efficacies by inhibiting only one enzyme with small molecules is unprecedented in pharmacology.  SAJE is focused on idiopathic pulmonary fibrosis and asthma as its first clinical applications, although there is animal data for efficacy in other diseases including cardiovascular, metabolic, inflammatory, liver, kidney, and other respiratory.  One GSNOR inhibitor has shown Clinical Proof of Concept for GSNOR as a target in a Phase IIa trial in asthma.

SAJE Pharma’s executive team consists of experienced drug development scientists and serial entrepreneurs whose backgrounds include FDA, large pharma, start-up companies, and the CRO industry.

SAJE has licensed one patent app that is nearing issuance in the EU and the US.  It protects SPL-334, SAJE’s lead molecule, and other related molecules.  In addition, SAJE is close to filing 3 more patent apps on its novel compositions that inhibit GSNOR.  A clear advantage for our drugs compared to many novel therapies  is the cost of goods.  Our drugs will cost pennies per dose.

SAJE would like to raise $15 MM to take SPL-334 through a Phase IIa trial in IPF.  The drug is ready for IND-enabling studies.  The company’s exit strategy is to out-license each of its drugs and their accompanying data set, one at a time, for different diseases in different categories.

Seroba Kernel is a venture capital firm based in Dublin, Ireland, with representatives in the United Kingdom. The firm has approximately €100M AUM and focuses solely on the life sciences. The firm has 2 funds and plans to raise a third fund in the near future. The firm typically allocates between €5-7M of equity over the life of the investment. The firm primarily invests in companies that are based in Ireland and Europe. Exceptional opportunities in North America will also be considered. The firm is actively seeking new investment opportunities.

Shire is an Irish-headquartered global specialty biopharmaceutical company. Originating in the United Kingdom with a large operational base in the United States, its brands and products include Vyvanse, Adderall XR, Intuniv, Lialda, Pentasa, Fosrenol, Replagal, Elaprase, VPRIV, Firazyr and Dermagraft. 

Shire is currently interested in several therapeutic areas for business development opportunities. The company is most interested in the following products: rare disease therapeutics, pre-clinical to on the market; neuroscience therapeutics, on the market; gastrointestinal, on the market; ophthalmology, post proof-of-concept; and hematology; post proof-of-concept.

Siragen Pharmaceuticals is a drug discovery and development company, focused on novel approaches to treat Aging and Neurodegenerative Disorders such as Alzheimer’s Disease. Siragen is developing a group of small lead molecules that tackles Alzheimer’s Disease and aging neurons by novel strategy different from current unsuccessful approaches.   Siragen Pharmaceuticals, based in San Diego, California, was incorporated in May 2014, and is a spin off of Neurogeneration Inc. Siragen's products will be for the brain what cholesterol agents are for the heart.